Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPN1 | P15169 | 3/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.40 |
| ▸ | DPP4 | P27487 | 13/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20601061 | 1.00 | CPN1 (0.40) | CPN1CPB2DPP4DPP7DPP8 | |
| SCHEMBL20600882 | 1.00 | CPN1 (0.40) | CPN1CPB2DPP4DPP7DPP8 | |
| SCHEMBL19064404 | 0.81 | DPP4 (0.40) | CPN1CPB2DPP4DPP7DPP8 | |
| SCHEMBL20601112 | 0.81 | DPP4 (0.40) | CPN1CPB2DPP4DPP7DPP8 | |
| SCHEMBL20600972 | 0.81 | DPP4 (0.40) | CPN1CPB2DPP4DPP7DPP8 | |
| SCHEMBL28351251 | 0.80 | CPN1 (0.37) | CPN1CPB2DPP4DPP7 | |
| SCHEMBL15140789 | 0.78 | MEN1 (0.42) | CPN1CPB2DPP4DPP7DPP8 | |
| SCHEMBL23827014 | 0.78 | CPN1 (0.40) | CPN1CPB2DPP4DPP7DPP8 | |
| SCHEMBL23827011 | 0.78 | CPN1 (0.40) | CPN1CPB2DPP4DPP7DPP8 | |
| SCHEMBL23825968 | 0.78 | DPP4 (0.41) | CPN1CPB2DPP4DPP7DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10927078-B2 | Modulators of indoleamine 2,3-dioxygenase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-02-23 | — | — | US | disclosed |
| US-20200165201-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-05-28 | — | — | US | disclosed |
| EP-3645520-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-05-06 | — | — | EP | disclosed |
| CN-110709391-A | Modulators of indoleamine2, 3-dioxygenase | 葛兰素史克知识产权开发有限公司 | 2020-01-17 | — | — | CN | disclosed |
| WO-2019003141-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200165201-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, TPH1 | CPN1 2717/4885CPB2 1401/4885DPP4 990/4885 |
| US-10927078-B2 | Modulators of indoleamine 2,3-dioxygenase | IDO1, IDO2, TPH1 | CPN1 2717/4885CPB2 1401/4885DPP4 990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.